Percentage of subjects achieving sustained virologic response 12 weeks post-treatment within each treatment group based on treatment duration [ Time Frame: 12 weeks after the last actual dose of study drug ] [ Designated as safety issue: No ]

Hepatitis C Virus ribonucleic acid less than the lower limit of quantification

Hepatitis C Virus ribonucleic acid less than the lower limit of quantification

The percentage of subjects with on-treatment Hepatitis C Virus virologic failure during the Treatment Period in each treatment group based on treatment duration [ Time Frame: up to 12 or 24 weeks based on treatment duration ] [ Designated as safety issue: No ]

The percentage of subjects with Hepatitis C Virus post-treatment relapse in each treatment group based on treatment duration [ Time Frame: within 12 weeks after the last dose of study drug ] [ Designated as safety issue: No ]

The percentage of subjects with confirmed quantifiable Hepatitis C Virus ribonucleic acid among subjects with unquantifiable Hepatitis C Virus ribonucleic acid at the end of treatment

The percentage of subjects with plasma human immunodeficiency virus, type 1 (HIV-1) ribonucleic acid suppression at the end of treatment and 12 weeks post-treatment for the treatment groups based on treatment duration [ Time Frame: up to 12 weeks after the last dose of study drug ] [ Designated as safety issue: No ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01939197